Conflicts of interest: No party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated. We certify that all financial and material support for this research has been clearly identified in the Funding section. Pat Reilly is an employee of Genentech, Inc.
A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III)
Version of Record online: 28 AUG 2013
© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization
International Journal of Stroke
Volume 9, Issue 4, pages 536–542, June 2014
How to Cite
Ziai, W. C., Tuhrim, S., Lane, K., McBee, N., Lees, K., Dawson, J., Butcher, K., Vespa, P., Wright, D. W., Keyl, P. M., Mendelow, A. D., Kase, C., Wijman, C., Lapointe, M., John, S., Thompson, R., Thompson, C., Mayo, S., Reilly, P., Janis, S., Awad, I., Hanley, D. F. and CLEAR III Investigators (2014), A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III). International Journal of Stroke, 9: 536–542. doi: 10.1111/ijs.12097
Funding: The CLEAR III trial is supported by a grant (NIH/NINDS 5U01 NS062851 to Dr Hanley). Drs Wendy Ziai and Stanley Tuhrim, Karen Lane, Nichol McBee, Drs Issam Awad, Kennedy Lees, Jesse Dawson, Kenneth Butcher, Paul Vespa, Penelope Keyl, A. David Mendelow, Carlos Kase, Christine Wijman, Marc Lapointe, Sayona John, Richard Thompson, Carol Thompson, and Steven Mayo receive funding from the same grant (NIH/NINDS 5U01 NS062851 to Dr Daniel F. Hanley). Dr Hanley is also supported by grants RO1NS046309 from the NIH/NINDS, grant 272–2007 from the Eleanor Naylor Dana Charitable Trust, the Jeffry and Harriet Legum Endowment, and materials grants from Genentech, Inc.
- Issue online: 5 MAY 2014
- Version of Record online: 28 AUG 2013
- Manuscript Accepted: 16 APR 2013
- Manuscript Received: 30 NOV 2012
- NIH/NINDS. Grant Numbers: 5U01 NS062851, RO1NS046309
- Eleanor Naylor Dana Charitable Trust. Grant Number: 272–2007
- Jeffry and Harriet Legum Endowment
- Genentech, Inc
- intracerebral haemorrhage;
- randomized clinical trial;
In adults, intraventricular thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) facilitates resolution of intraventricular haemorrhage (IVH), reduces intracranial pressure, decreases duration of cerebrospinal fluid diversion, and may ameliorate direct neural injury. We hypothesize that patients with small parenchymal haematoma volumes (<30 cc) and relatively large IVH causing acute obstructive hydrocephalus would have improved clinical outcomes when given injections of low-dose rtPA to accelerate lysis and evacuation of IVH compared with placebo.
The Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage III trial is an investigator-initiated, phase III, randomized, multicenter, double-blind, placebo-controlled study comparing the use of external ventricular drainage (EVD) combined with intraventricular injection of rtPA to EVD plus intraventricular injection of normal saline (placebo) for the treatment of IVH. Patients with known symptom onset within 24 h of the computed tomography scan confirmed IVH and third or fourth ventricle obstruction, with or without supratentorial intracerebral haemorrhage volume <30 cc, who require EVD are screened with a computed tomography scan at least six hours after EVD placement and, if necessary, at consecutive 12-h intervals until stabilization of any intracranial bleeding has been established. Patients who meet clinical and imaging criteria (no ongoing coagulopathy and no suspicion of aneurysm, arteriovenous malformation, or any other vascular anomaly) will be randomized to either intraventricular rtPA or placebo.
The primary outcome measure is dichotomized modified Rankin Scale 0–3 vs. 4–6 at 180 days. Clinical secondary outcomes include additional modified Rankin Scale dichotomizations at 180 days (0–4 vs. 5–6), ordinal modified Rankin Scale (0–6), mortality and safety events at 30 days, mortality at 180 days, functional status measures, type and intensity of intensive care unit management, rate and extent of ventricular blood clot removal, and quality of life measures.